Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation After Direct-Acting Antivirals in HCV Cirrhotic Patients

Abstract

Purpose Little evidence is available regarding the risk of hepatic decompensation (HD) after direct-acting antivirals (DAAs) in patients with advanced chronic liver disease. Our aim was to assess the risk of decompensation and the prognostic role of noninvasive tests, such as liver (LSM) and spleen (SSM) stiffness measurements, in the prediction of decompensation after sustained virologic response (SVR) by DAAs.

Materials and Methods A cohort study involving 146 cirrhotic patients treated with DAAs in our tertiary center with LSM and SSM available both before and six months after treatment (SVR24). A historical cohort of 92 consecutive cirrhotic patients with active HCV was used as a control group. A propensity score inverse probability weighting method was used to account for differences between the groups. Time-dependent models for the prediction of decompensation were applied to account for changes in noninvasive tests after therapy.

Results The decompensation incidence in the DAA cohort was 7.07 (4.56–10.96) per 100 person-years (PYs), which was significantly lower than in the active HCV cohort. The DAA therapy was an independent protective factor for HD development (SHR: 0.071, 95 %-CI: 0.015–0.332). SSM ≥ 54 kPa was independently associated with decompensation despite SVR achievement (SHR: 4.169, 95 %-CI: 1.050–16.559), alongside with a history of decompensation (SHR: 7.956, 95 %-CI: 2.556–24.762). SSM reduction < 10 % also predicted the risk of decompensation after SVR24.

Conclusion The risk of decompensation was markedly reduced after DAA therapy, but it was not eliminated. Paired SSM values stratified the risk of decompensation after SVR better than other noninvasive tests.

Zusammenfassung

Ziel Über das Risiko einer hepatischen Dekompensation (HD) nach direkt antiviral wirksamen Substanzen (DAA) bei Patienten mit fortgeschrittener chronischer Lebererkrankung gibt es nur wenig Evidenz. Unser Ziel war es, das Risiko einer Dekompensation und den prognostischen Wert nichtinvasiver Tests wie Messungen der Lebersteifigkeit (LSM) und Milzsteifigkeit (SSM) zur Vorhersage einer Dekompensation nach anhaltendem virologischem Ansprechen (SVR) unter DAA zu bewerten.

Material und Methoden Kohortenstudie mit 146 Zirrhose-Patienten, die in unserem Tertiärzentrum mit DAAs behandelt wurden, wobei LSM und SSM sowohl vor als auch 6 Monate nach der Behandlung verfügbar waren (SVR24). Eine historische Kohorte von 92 konsekutiven zirrhotischen Patienten mit aktiver HCV wurde als Kontrollgruppe verwendet. Um die Unterschiede zwischen den Gruppen zu berücksichtigen, wurde die Propensity-Score-Methode („inverse probability weighting“) verwendet. Zeitabhängige Modelle zur Prädiktion der Dekompensation wurden angewandt, um Veränderungen in den nichtinvasiven Tests nach Therapie zu berücksichtigen.

Ergebnisse Die Dekompensations-Inzidenz in der DAA-Kohorte betrug 7,07 (4,56–10,96) pro 100 Personenjahre (PYs), was signifikant niedriger war als in der aktiven HCV-Kohorte. Die DAA-Therapie war ein unabhängiger protektiver Faktor für die Entwicklung einer HD (SHR: 0,071; 95 %-KI 0,015–0,332). SSM ≥ 54kPa war trotz erfolgreichem SVR unabhängig mit Dekompensation assoziiert (SHR: 4,169; 95 %-KI 1,050–16,559), zusammen mit früher aufgetretener Dekompensation (SHR: 7,956; 95 %-KI 2,556–24,762). Eine SSM-Reduktion < 10 % sagte auch das Risiko einer Dekompensation nach SVR24 voraus.

Schlussfolgerung Das Risiko einer Dekompensation war nach DAA-Therapie deutlich reduziert, aber nicht eliminiert. Gepaarte SSM-Werte stratifizierten das Risiko einer Dekompensation nach SVR besser als andere nichtinvasive Tests.

Key words

spleen stiffness measurement - liver stiffness measurement - transient elastography - sustained virologic response - abdomen

Publication History

Received: 02 October 2019

Accepted: 31 May 2020

Article published online:
16 July 2020

• References

• 1 Ioannou GN, Beste LA, Chang MF. et al. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology 2016; 151: 457-471.e5
• 2 Flisiak R, Janczewska E, Łucejko M. et al. Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study. J Viral Hepat 2018; 25 (11) 1298-1305
• 3 Lens S, Alvarado E, Mariño Z. et al. Effects of All-oral Anti-viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-associated Cirrhosis. Gastroenterology 2017; 153 (05) 1273-1283.e1
• 4 Pawlotsky JM, Negro F, Aghemo A. et al. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018; 69: 461-511
• 5 Conti F, Buonfiglioli F, Scuteri A. et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65: 727-733
• 6 Nahon P, Layese R, Bourcier V. et al. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology 2018; 155 (05) 1436-1450.e6
• 7 Ioannou GN, Green PK, Beste LA. et al. Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C. J Hepatol 2018; 69 (05) 1088-1098
• 8 Kanwal F, Kramer J, Asch SM. et al. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology 2017; 153 (04) 996-1005.e1
• 9 Ioannou GN, Feld JJ. What are the Benefits of a Sustained Virologic Response to Direct-acting Antiviral Therapy for HCV Infection?. Gastroenterology 2019; 156 (02) 446-460.e2
• 10 Park H, Wang W, Henry L. et al. Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C patients in the U.S. Hepatology 2018; 69 (03) 1032-1045
• 11 Berzigotti A. Non invasive evaluation of portal hypertension using ultrasound elastography. J Hepatol 2017; 67 (02) 399-411
• 12 de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63: 743-752
• 13 Song J, Ma Z, Huang J. et al. Comparison of three cut-offs to diagnose clinically significant portal hypertension by liver stiffness in chronic viral liver diseases: a meta-analysis. Eur Radiol 2018; 28 (12) 5221-5230
• 14 Manatsathit W, Samant H, Kapur S. et al. Accuracy of liver stiffness, spleen stiffness, and LS-spleen diameter to platelet ratio score in detection of esophageal varices: Systemic review and meta-analysis. J Gastroenterol Hepatol 2018; 33 (10) 1696-1706
• 15 Colecchia A, Ravaioli F, Marasco G. et al A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease. J Hepatol 2018; 69 (02) 308-317 . doi:10.1016/j.jhep.2018.04.023
• 16 Colecchia A, Colli A, Casazza G. et al Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: A prospective study. J Hepatol 2014; 60: 1158-1164 . doi:10.1016/j.jhep.2014.02.024
• 17 Singh S, Fujii LL, Murad MH. et al Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1573-1584.e1–2 ; quiz e88–89
• 18 Pons M, Santos B, Simón-Talero M. et al. Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. Therap Adv Gastroenterol 2017; 10: 619-829. e8
• 19 Knop V, Hoppe D, Welzel T. et al. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat 2016; 23 (12) 994-1002
• 20 Ravaioli F, Colecchia A, Dajti E. et al Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients. World J Hepatol 2018; 10: 731-742 . doi:10.4254/wjh.v10.i10.731
• 21 Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 2014; 33: 1242-1258
• 22 Angeli P, Bernardi M, Villanueva C. et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406-460
• 23 Dietrich CF, Bamber J, Berzigotti A. et al. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). Ultraschall in der Medizin 2017; 38: e16-e47
• 24 Llop E, Berzigotti A, Reig M. et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol 2012; 56: 103-108
• 25 Dajti E, Ravaioli F, Festi D. et al Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk. Hepatobiliary Surg Nutr 2019; epub ahead of print DOI: 10.21037/hbsn.2019.11.19.
• 26 Carrat F, Fontaine H, Dorival C. et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019; 393: 1453-1464
• 27 Mauro E, Crespo G, Montironi C. et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after SVR in recurrent hepatitis C. Hepatology 2018; 67 (05) 1683-1694
• 28 Mandorfer M, Kozbial K, Schwabl P. et al Changes in HVPG predict hepatic decompensation in patients who achieved SVR to IFN‐free therapy. Hepatology 2020; 71 (03) 1023-1036 . hep.30885
• 29 Kim HY, So YH, Kim W. et al. Noninvasive Response Prediction in Prophylactic Carvedilol Therapy for Cirrhotic Patients with Esophageal Varices. J Hepatol 2018; 70 (03) 412-422
• 30 Bastard C, Miette V, Calès P. et al. A Novel FibroScan Examination Dedicated to Spleen Stiffness Measurement. Ultrasound Med Biol 2018; 44: 1616-1626